Modern Determination of Complement Activation

 

 Buy Article Permissions and Reprints

ABSTRACT

Modern, that is, accurate determination of complement activation in vivo requires the simultaneous determination of both naive and activated complement proteins. This is best achieved by the use of native-restricted and neoepitope-specific monoclonal antibodies in sensitive enzyme-linked immunosorbent assays. Several confounding factors also have to be taken into account to allow a correct interpretation of the results.

REFERENCES

• 1 Speth C, Würzner R, Stoiber H, Dierich M P. Complement. In: Paul WE Fundamental Immunology. Philadelphia, PA; Lippincott Williams & Wilkins 2008: 1047-1078
  PubMedGoogle Scholar
• 2 Mollnes T E, Harboe M. Neoepitope expression during complement activation—a model for detecting antigenic changes in proteins and activation of cascades.  Immunologist. 1993;  1 43-49
  PubMedGoogle Scholar
• 3 Mollnes T E, Jokiranta T S, Truedsson L, Nilsson B, Rodriguez de Cordoba S, Kirschfink M. Complement analysis in the 21st century.  Mol Immunol. 2007;  44(16) 3838-3849
  CrossrefPubMedGoogle Scholar
• 4 Oppermann M, Höpken U, Götze O. Assessment of complement activation in vivo.  Immunopharmacology. 1992;  24(2) 119-134
  CrossrefPubMedGoogle Scholar
• 5 Giclas P C. Evaluation of complement activation and its clinical relevance. In: Detrick B, Hamilton RG, Folds JD Manual of Molecular and Clinical Laboratory Immunology. Washington, DC; ASM Press 2006: 115-117
  PubMedGoogle Scholar
• 6 Würzner R, Mollnes T E, Morgan B P. Immunochemical assays for complement components. In: Johnstone AP, Turner MW Immunochemistry 2: A Practical Approach. Oxford, United Kingdom; Oxford University Press 1997: 197-223
  PubMedGoogle Scholar
• 7 Morgan B P. Complement. In: van Oss CJ, van Regenmortel MHV Immunochemistry. New York, NY; Marcel Decker 1994: 903-919
  PubMedGoogle Scholar
• 8 Jahns G, Haeffner-Cavaillon N, Nydegger U E, Kazatchkine M D. Complement activation and cytokine production as consequences of immunological bioincompatibility of extracorporeal circuits.  Clin Mater. 1993;  14(4) 303-336
  CrossrefPubMedGoogle Scholar
• 9 Harrison R A. Purification, assay, characterisation of complement proteins from plasma. In: Herzenberg LA, Wier DM, Herzenberg LA, Blackwell C Weir's Handbook of Experimental Immunology. Oxford, United Kingdom; Blackwell 1996: 75.1-75.50
  PubMedGoogle Scholar
• 10 Mayer M M. Complement and complement fixation. In: Kabat EA, Mayer MM Experimental Immunochemistry. 2nd ed. Springfield, IL; Charles C. Thomas 1961: 149-172
  PubMedGoogle Scholar
• 11 Seelen M A, Roos A, Wieslander J et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA.  J Immunol Methods. 2005;  296(1–2) 187-198
  CrossrefPubMedGoogle Scholar
• 12 Guo R F, Ward P A. Role of C5a in inflammatory responses.  Annu Rev Immunol. 2005;  23 821-852
  CrossrefPubMedGoogle Scholar
• 13 Chenoweth D E. The properties of human C5a anaphylatoxin. The significance of C5a formation during hemodialysis.  Contrib Nephrol. 1987;  59 51-71
  PubMedGoogle Scholar
• 14 Aguado M T, Lambris J D, Tsokos G C et al. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.  J Clin Invest. 1985;  76(4) 1418-1426
  CrossrefPubMedGoogle Scholar
• 15 Garred P, Mollnes T E, Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3.  Scand J Immunol. 1988;  27(3) 329-335
  CrossrefPubMedGoogle Scholar
• 16 Würzner R, Orren A, Potter P et al. Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals.  Clin Exp Immunol. 1991;  83(3) 430-437
  CrossrefPubMedGoogle Scholar
• 17 Würzner R, Schulze M, Happe L et al. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.  Complement Inflamm. 1991;  8(5–6) 328-340
  PubMedGoogle Scholar
• 18 Würzner R. Monoclonal antibodies against the terminal complement components. In: Sim RB Activators and Inhibitors of Complement. Dordrecht, The Netherlands; Kluwer Academic Publishers 1993: 167-180
  PubMedGoogle Scholar
• 19 Hugli T E, Chenoweth D E. Biologically active peptides of complement: techniques and significance of C3a and C5a measurements. In: Nakamura RM, Dito WR, Tucker ES Immunoassays: Clinical Laboratory Techniques for the 1980s. New York, NY; A.R. Liss 1980: 443-460
  PubMedGoogle Scholar
• 20 Zilow G, Naser W, Rutz R, Burger R. Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope.  J Immunol Methods. 1989;  121(2) 261-268
  CrossrefPubMedGoogle Scholar
• 21 Oppermann M, Schulze M, Götze O. A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope.  Complement Inflamm. 1991;  8(1) 13-24
  PubMedGoogle Scholar
• 22 Takeda J, Kinoshita T, Takata Y et al. Rapid and simple measurement of human C5a-des-Arg level in plasma or serum using monoclonal antibodies.  J Immunol Methods. 1987;  101(2) 265-270
  CrossrefPubMedGoogle Scholar
• 23 Bergh K, Iversen O J. Measurement of complement activation in rabbit plasma or serum using monoclonal antibodies against C5a.  J Immunol Methods. 1992;  152 79-87
  CrossrefPubMedGoogle Scholar
• 24 Oppermann M, Baumgarten H, Brandt E, Gottsleben W, Kurts C, Götze O. Quantitation of components of the alternative pathway of complement (APC) by enzyme-linked immunosorbent assays.  J Immunol Methods. 1990;  133(2) 181-190
  CrossrefPubMedGoogle Scholar
• 25 Kolb W P, Morrow P R, Tamerius J D. Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples.  Complement Inflamm. 1989;  6(3) 175-204
  PubMedGoogle Scholar
• 26 Teisner B, Brandslund I, Grunnet N, Hansen L K, Thellesen J, Svehag S E. Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation.  J Clin Lab Immunol. 1983;  12(2) 63-67
  PubMedGoogle Scholar
• 27 Nuijens J H, Huijbregts C C, Eerenberg-Belmer A J et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis.  Blood. 1988;  72(6) 1841-1848
  PubMedGoogle Scholar
• 28 Nuijens J H, Huijbregts C C, van Mierlo G M, Hack C E. Inactivation of C-1 inhibitor by proteases: demonstration by a monoclonal antibody of a neodeterminant on inactivated, non-complexed C-1 inhibitor.  Immunology. 1987;  61(3) 387-389
  PubMedGoogle Scholar
• 29 Cugno M, Nuijens J, Hack E et al. Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.  J Clin Invest. 1990;  85(4) 1215-1220
  CrossrefPubMedGoogle Scholar
• 30 Zilow G, Sturm J A, Rother U, Kirschfink M. Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome.  Clin Exp Immunol. 1990;  79(2) 151-157
  CrossrefPubMedGoogle Scholar
• 31 Tschopp J, Mollnes T E. Antigenic crossreactivity of the alpha subunit of complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor.  Proc Natl Acad Sci U S A. 1986;  83(12) 4223-4227
  CrossrefPubMedGoogle Scholar
• 32 Richards S J, Hill A, Hillmen P. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria.  Cytometry B Clin Cytom. 2007;  72(5) 291-298
  PubMedGoogle Scholar
• 33 Oliveira J B, Notarangelo L D, Fleisher T A. Applications of flow cytometry for the study of primary immune deficiencies.  Curr Opin Allergy Clin Immunol. 2008;  8(6) 499-509
  CrossrefPubMedGoogle Scholar
• 34 Mollnes T E, Garred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation.  Clin Exp Immunol. 1988;  73(3) 484-488
  PubMedGoogle Scholar
• 35 Ruddy S, Carpenter C B, Chin K W et al. Human complement metabolism: an analysis of 144 studies.  Medicine (Baltimore). 1975;  54 165-178
  PubMedGoogle Scholar
• 36 Buyon J P, Cronstein B N, Morris M, Tanner M, Weissmann G. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia.  Am J Med. 1986;  81(2) 194-200
  CrossrefPubMedGoogle Scholar
• 37 Sliwinski A J, Zvaifler N J. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus.  Clin Exp Immunol. 1972;  11(1) 21-29
  PubMedGoogle Scholar
• 38 Atkinson J P. Complement deficiency. Predisposing factor to autoimmune syndromes.  Am J Med. 1988;  85(6A, 6A) 45-47
  PubMedGoogle Scholar
• 39 Hebert L A, Cosio F G, Neff J C. Diagnostic significance of hypocomplementemia.  Kidney Int. 1991;  39(5) 811-821
  CrossrefPubMedGoogle Scholar
• 40 Hecker L A, Edwards A O, Ryu E et al. Genetic control of the alternative pathway of complement in humans and age-related macular degeneration.  Hum Mol Genet. 2010;  19(1) 209-215
  CrossrefPubMedGoogle Scholar
• 41 de Jong P T. Age-related macular degeneration.  N Engl J Med. 2006;  355(14) 1474-1485
  CrossrefPubMedGoogle Scholar
• 42 Esparza-Gordillo J, Soria J M, Buil A et al. Genetic and environmental factors influencing the human factor H plasma levels.  Immunogenetics. 2004;  56(2) 77-82
  CrossrefPubMedGoogle Scholar
• 43 Esparza-Gordillo J, Soria J M, Buil A et al. Genetic determinants of variation in the plasma levels of the C4b-binding protein (C4BP) in Spanish families.  Immunogenetics. 2003;  54(12) 862-866
  PubMedGoogle Scholar
• 44 Roach B, Kim Y, Jerome E, Michael A F. Influence of age and sex on serum complement components in children.  Am J Dis Child. 1981;  135(10) 918-920
  PubMedGoogle Scholar
• 45 Sonntag J, Brandenburg U, Polzehl D et al. Complement system in healthy term newborns: reference values in umbilical cord blood.  Pediatr Dev Pathol. 1998;  1(2) 131-135
  CrossrefPubMedGoogle Scholar
• 46 Scholl H P, Charbel Issa P, Walier M et al. Systemic complement activation in age-related macular degeneration.  PLoS One. 2008;  3(7) e2593
  CrossrefPubMedGoogle Scholar
• 47 Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso A P. Effect of body weight and caloric restriction on serum complement proteins, including factor D/adipsin: studies in anorexia nervosa and obesity.  Clin Exp Immunol. 1997;  108(3) 507-515
  CrossrefPubMedGoogle Scholar
• 48 Oppermann M, Haubitz M, Quentin E, Götze O. Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B.  Klin Wochenschr. 1988;  66(18) 857-864
  CrossrefPubMedGoogle Scholar
• 49 Craddock P R, Fehr J, Dalmasso A P, Brighan K L, Jacob H S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.  J Clin Invest. 1977;  59(5) 879-888
  CrossrefPubMedGoogle Scholar
• 50 Höpken U, Mohr M, Strüber A et al. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies.  Eur J Immunol. 1996;  26(5) 1103-1109
  CrossrefPubMedGoogle Scholar
• 51 Oppermann M, Götze O. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.  Immunology. 1994;  82(4) 516-521
  PubMedGoogle Scholar
• 52 Mollnes T E. Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex.  Complement. 1985;  2(2–3) 156-164
  PubMedGoogle Scholar
• 53 Deppisch R, Schmitt V, Bommer J, Hänsch G M, Ritz E, Rauterberg E W. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility.  Kidney Int. 1990;  37(2) 696-706
  CrossrefPubMedGoogle Scholar
• 54 Volanakis J E, Barnum S R, Giddens M, Galla J H. Renal filtration and catabolism of complement protein D.  N Engl J Med. 1985;  312(7) 395-399
  CrossrefPubMedGoogle Scholar
• 55 Oppermann M, Kurts C, Zierz R, Quentin E, Weber M H, Götze O. Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure.  Kidney Int. 1991;  40(5) 939-947
  CrossrefPubMedGoogle Scholar
• 56 Pascual M, Paccaud J P, Macon K, Volanakis J E, Schifferli J A. Complement activation by the alternative pathway is modified in renal failure: the role of factor D.  Clin Nephrol. 1989;  32(4) 185-193
  PubMedGoogle Scholar
• 57 Matthews K W, Mueller-Ortiz S L, Wetsel R A. Carboxypeptidase N: a pleiotropic regulator of inflammation.  Mol Immunol. 2004;  40(11) 785-793
  CrossrefPubMedGoogle Scholar
• 58 Oppermann M, Götze O. Characterization of physiologic breakdown products of the complement fragment Ba.  Mol Immunol. 1994;  31(4) 307-314
  CrossrefPubMedGoogle Scholar
• 59 Garred P, Mollnes T E, Kazatchkine M D. Activation-dependent antigenic changes of human C3.  Complement Inflamm. 1989;  6(3) 205-218
  PubMedGoogle Scholar

Martin OppermannM.D. 

Abteilung Zelluläre und Molekulare Immunologie, Zentrum für Hygiene und Humangenetik

Humboldtallee 34, D-37075 Göttingen, Germany

Email: mopperm@gwdg.de